P193 Clinical features of patients with active ankylosing spondylitis who did not respond to adalimumab but responded to ixekizumab: a post-hoc analysis
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab247.188
Abstract: Background/Aims Biologic treatment in ankylosing spondylitis (AS) are currently limited to TNF and IL-17A inhibitors (IL-17Ai). It is unknown whether there are predictors of AS patients who only respond to 1 of these mechanisms of… read more here.
Keywords: ixe; eli lilly; novartis; shareholder ... See more keywords
P127 Baricitinib Efficacy in Moderate Rheumatoid Arthritis - A Post-hoc Analysis from two Phase III Trials
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.168
Abstract: Baricitinib, an oral selective JAK 1/2 inhibitor, is approved for treating adults with moderate-to-severe active rheumatoid arthritis (RA). This analysis aims to report the efficacy of baricitinib in patients with moderate RA at weeks (W)12… read more here.
Keywords: lilly company; analysis; eli lilly; research support ... See more keywords
P131 Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.172
Abstract: RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with rheumatoid arthritis (RA) evaluating time-to-discontinuation of initial RA treatment. Baricitinib (BARI), an oral selective JAK1/2 inhibitor, is approved for the treatment of adults… read more here.
Keywords: time; lilly company; eli lilly; discontinuation ... See more keywords
P169 Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.210
Abstract: Psoriatic nail disease is intimately linked to adjacent distal interphalangeal joint (DIP) disease, and it is important to ascertain whether DIP-nail complex behaves differently under different biological therapies. The aim of this analysis is to… read more here.
Keywords: lilly company; novartis; involvement; janssen ... See more keywords
P184 A 24-month prospective psoriatic arthritis observational study of persistence of treatment - interim analysis of baseline characteristics
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.225
Abstract: Ixekizumab (ixe), a highly selective interleukin (IL)-17A monoclonal antibody, has been approved for treatment of psoriatic arthritis (PsA). However, there is limited real-world evidence (RWE) available for ixe. PRO-SPIRIT is the first large-sample prospective observational… read more here.
Keywords: lilly company; treatment; eli lilly; research support ... See more keywords
FRI0096 Durability and maintenance of efficacy following prolonged treatment with baricitinib
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1311
Abstract: Background Baricitinib (bari) demonstrated clinical efficacy in Ph3 trials in RA patients (pts) naïve to DMARDs (RA-BEGIN1); and in RA pts with inadequate response to conventional synthetic DMARDs (RA-BEAM2 and RA-BUILD3) or biologic DMARDs (RA-BEACON4).… read more here.
Keywords: response; lilly company; eli lilly; durability ... See more keywords
FRI0090 Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1325
Abstract: Background Rheumatoid arthritis (RA) is associated with increased neutrophil levels1 and platelet2 counts and decreased lymphocyte levels.1,3 Baricitinib (bari) is a selective and reversible Janus kinase (JAK)1/JAK2 inhibitor in development for patients (pts) with moderate… read more here.
Keywords: eli lilly; lilly company; phase; employee eli ... See more keywords
AB0281 Characterization of changes in lymphocyte subsets in baricitinib-treated patients with early, dmard naÏve, rheumatoid arthritis in a phase 3 study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1336
Abstract: Background In RA-BEGIN (NCT01711359), baricitinib (bari), an oral Janus Kinase (JAK)1/JAK2 inhibitor, improved signs and symptoms of moderately to severely active RA in patients (pts) who had received no or limited prior csDMARD and no… read more here.
Keywords: lilly company; eli lilly; mtx; cell ... See more keywords
AB0235 Effect of baseline disease activity on achieving sustained low disease activity in baricitinib phase 3 studies
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1340
Abstract: Background In the Phase 3 studies RA-BUILD1 and RA-BEAM2, baricitinib (bari) has demonstrated clinical efficacy including reduced disease activity in RA patients (pts) with an inadequate response (IR) to conventional synthetic DMARDs (csDMARDs). Objectives To… read more here.
Keywords: eli lilly; lilly company; disease activity; disease ... See more keywords
THU0114 Effects of smoking on baricitinib efficacy in patients with rheumatoid arthritis: pooled analysis from two phase 3 clinical trials
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1341
Abstract: Background The efficacy of some rheumatoid arthritis (RA) therapies is reduced among patients who are smokers. Objectives This post-hoc analysis of two phase 3 studies assessed the effects of patient smoking status on the response… read more here.
Keywords: baricitinib; lilly company; analysis; efficacy ... See more keywords
AB0240 Reduction in fatigue and pain are associated with improved work productivity in patients with ra
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1932
Abstract: Background Despite current treatment options, patients with rheumatoid arthritis (RA) report fatigue and pain, important determinants of quality of life.1 In prior analyses of a Phase 3 trial of baricitinib (RA-BEAM), baricitinib demonstrated superiority in… read more here.
Keywords: work; lilly company; eli lilly; work productivity ... See more keywords